The Babak Lab, shared on LinkedIn:
“Can ferroptosis make cancer vaccines more effective?
Dendritic cell (DC) vaccines are great on paper, but their clinical impact on aggressive tumors like glioma has been modest. A recent study in Nature Communications offers a clever workaround: pre-treating tumor cells with ferroptosis before using their lysates to load DCs.
Key Insights:
- DCs loaded with ferroptotic glioma lysates triggered strong anti-tumor immunity and prolonged survival in mice.
- The treatment drove high CD8+ T-cell infiltration, boosted IFN-γ production, and generated long-term effector memory T-cells.
- The effect held true across multiple glioma models (GL261, CT-2A) and different ferroptosis inducers (RSL3, SAS).
- DAMP-dependent, but unique: Vaccine efficacy relied on calreticulin (CRT) and ATP, but not on HMGB1-TLR4 pathways.
- Simply mixing synthetic CRT and ATP into standard tumor lysates couldn’t replicate the effect – proving that ferroptosis alters the tumor material in a way that raw DAMP supplements cannot match.
Why this matters:
Instead of relying on ferroptosis solely to kill tumor cells directly, this study repurposes it as an upstream ‘bio-factory’ to generate highly immunogenic cancer vaccines. It’s a pragmatic shift that could help bridge the gap between DC vaccine theory and actual clinical efficacy in solid tumors”.
Tilte: Ferroptosis-armed dendritic cell vaccines for glioma immunotherapy
Authors: Mariia Saviuk, Victoria D. Turubanova, Sara De Brée, Sandra Van Lint, Teresa Mendes Maia, Simon Devos, Iuliia Efimova, Julie Braet, Lore Van Oudenhove, Gitta Boons, Faye Naessens, Robin Demuynck, Ellen Saeys, Christian Vanhove, Lukas Bunse, Peter M. van Endert, Robrecht Raedt, Maria V. Vedunova, Olga Krysko, Roosmarijn E. Vandenbroucke, Karim Vermaelen, Tatiana A. Mishchenko, Elena Catanzaro, Dmitri V. Krysko
Read The Full Article
